Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

An oncology team evaluates a 59-year-old male with metastatic melanoma before administering his next scheduled dose of pembrolizumab. He reports feeling unusually anxious and sweaty over the past two weeks, along with experiencing mild hand tremors. He has no other medical history. Vital signs show a blood pressure of 135/82 mm Hg135/82 \text{ mm Hg} and a regular pulse of 110 /min110 \text{ /min}. Physical examination reveals a fine action tremor and warm, moist skin, but no focal abdominal or pulmonary findings. Laboratory results demonstrate a thyroid-stimulating hormone (TSH) level of <0.01μU/mL<0.01 \mu\text{U/mL} (normal: 0.5−5.0μU/mL0.5-5.0 \mu\text{U/mL}) and a free T4 of 2.8 ng/dL2.8 \text{ ng/dL} (normal: 0.8−1.8 ng/dL0.8-1.8 \text{ ng/dL}). His hepatic and renal function panels are within normal limits. Which of the following is the most appropriate next step in the management of this patient?

  1. Continue pembrolizumab and prescribe a beta-adrenergic antagonistAnswer
  2. B
    Suspend pembrolizumab and initiate systemic glucocorticoid therapy
  3. C
    Continue pembrolizumab and prescribe methimazole
  4. D
    Permanently discontinue pembrolizumab and refer for radioactive iodine ablation
  5. E
    Withhold pembrolizumab and obtain a thyroid ultrasound with Doppler flow

Answer

Continue pembrolizumab and prescribe a beta-adrenergic antagonist.
The patient is experiencing immune checkpoint inhibitor (ICI)-induced thyroiditis, a well-recognized endocrine immune-related adverse event (irAE) associated with PD-1 inhibitors like pembrolizumab. It typically presents as a painless, destructive thyroiditis with a transient thyrotoxic phase (suppressed TSH, elevated free T4) followed by permanent hypothyroidism. Unlike other organ-specific irAEs (e.g., pneumonitis, colitis, hepatitis) which often require prompt discontinuation of the ICI and initiation of high-dose systemic corticosteroids, endocrine irAEs are a notable exception. For Grade 1 or 2 ICI-induced hyperthyroidism, the standard of care is to continue the immunotherapy and manage hyperadrenergic symptoms with a beta-adrenergic antagonist (e.g., propranolol). Patients must be monitored closely with serial thyroid function tests, as the transition to hypothyroidism often occurs within weeks and subsequently requires lifelong levothyroxine supplementation.

Step-by-Step Solution

1
Interpret the clinical and laboratory presentation.
The patient has thyrotoxicosis (suppressed TSH, elevated free T4) with symptomatic tachycardia and tremor developing shortly after starting pembrolizumab.
Establishing the etiology of thyrotoxicosis is essential for determining the safest and most effective management strategy.
2
Identify the underlying mechanism of the adverse event.
Pembrolizumab, an immune checkpoint inhibitor, frequently causes immune-related adverse events (irAEs), including destructive thyroiditis characterized by a transient release of preformed thyroid hormone.
Recognizing this as destructive thyroiditis rather than increased hormone synthesis (e.g., Graves disease) dictates the correct pharmacologic approach.
3
Select the appropriate treatment modification and monitoring strategy.
Systemic corticosteroids and immunotherapy suspension are not required. Beta-blockers should be initiated for symptom control while the cancer therapy continues.
Endocrine irAEs uniquely do not require immunosuppression, allowing life-saving cancer therapy to continue uninterrupted while symptoms are managed.

Key Concept

Immune checkpoint inhibitor-induced thyroiditis typically presents with a transient thyrotoxic phase that should be managed with symptom control (e.g., beta-blockers) while continuing the immunotherapy. It does not require systemic corticosteroids or treatment discontinuation.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic